Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06048887 · ClinicalTrials.gov registry record · Phase 1
Single and Multiple-Ascending Dose Study of CRN04894 in Healthy Volunteers
A Phase 1 study, sponsored by Crinetics Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT06048887 is a Phase 1 study that has completed, run by Crinetics Pharmaceuticals. The registered enrollment target is 88 participants.
The verdict
NCT06048887, a Phase 1 study, has completed, sponsored by Crinetics Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
A Phase 1, first-in-human, double-blind, randomized, placebo-controlled study to evaluate the safety of CRN04894 in healthy volunteers as well as the relationship between exposure and pharmacodynamic (PD) parameters.
Interventions
- DRUG Placebo Oral Solution
- DRUG CRN04894 Oral Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2020-12-18 |
| Est. Completion | 2022-04-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06048887
The ClinicalTrials.gov registry entry for NCT06048887 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Crinetics Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Solution is the first listed.
NCT06048887 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06048887 about?
NCT06048887 is a clinical study titled "Single and Multiple-Ascending Dose Study of CRN04894 in Healthy Volunteers". A Phase 1, first-in-human, double-blind, randomized, placebo-controlled study to evaluate the safety of CRN04894 in healthy volunteers as well as the relationship between exposure and pharmacodynamic (PD) parameters.
What is the current status of trial NCT06048887?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2020-12-18. Estimated completion is 2022-04-11.
What interventions are being tested in trial NCT06048887?
The interventions under investigation include: Placebo Oral Solution (DRUG), CRN04894 Oral Solution (DRUG).
Who is sponsoring clinical trial NCT06048887?
This trial is sponsored by Crinetics Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.